ANCA against the bactericidal/permeability increasing protein (BPI-ANCA) can compromise the antibiotic function of BPI in a Wegener's granulomatosis patient

Clinical and Experimental Rheumatology

Volumn 21, Issue 6, 2003, Pages 763-766

  Schultz, Hendrik ^a,c   Heintz, H ^a   van Zandbergen, G ^b   Ullrich, S ^a   Reinhold Keller, E ^a   Gross, W L ^a  

^a Poliklinik fur Rheumatologie   (Germany)

^b Institut fur Med Mikrobiol Hygiene   (Germany)

^c Division of Infectious Diseases   (United States)

Author keywords

Antineutrophil cytoplasmic antibodies; Innate immunity; Vasculitides

Indexed keywords

ANTIBIOTIC AGENT; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; INFLIXIMAB; LEFLUNOMIDE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL GROWTH; CASE REPORT; GRAM NEGATIVE INFECTION; GROWTH INHIBITION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LUNG LAVAGE; MALE; PRIORITY JOURNAL; RELAPSE; REMISSION; RESPIRATORY TRACT INFECTION; SUBGLOTTIC STENOSIS; WEGENER GRANULOMATOSIS;

ANTI-BACTERIAL AGENTS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; BLOOD BACTERICIDAL ACTIVITY; CELL MEMBRANE PERMEABILITY; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MIDDLE AGED; PNEUMONIA, BACTERIAL; RISK ASSESSMENT; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 0346258209     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. GROSS WL: Antineutrophil cytoplasmic autoantibody testing in vasculitides. Rheum Dis Clin North Am 1995; 21: 987-1011.
2. ZHAO MH, JONES SJ, LOCKWOOD CM: Bactericidal/permeability increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol 1995; 99: 49-56.
3. STOFFEL MP, CSERNOK E, HERZBERG C, JOHNSTON T, CARROLL SF, GROSS WL: Antineutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): A new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol 1996; 104: 54-9.
4. MAHADEVA R, DUNN AC, WESTERBEEK RC et al.: Anti-neutrophil cytoplasmic antibodies (ANCA)against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease. Clin Exp Immunol 1999; 117: 561-7.
5. IOVINE NM, ELSBACH P, WEISS J: An opsonic function of the neutrophil bactericidal/permeability increasing protein depends on both its N- and C-terminal domains. Proc Natl Acad Sci USA 1997; 94: 10973-8.
6. HAGEN EC, DAHA MR, HERMANS J et al.: Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for Assay Standardization. Kidney Int 1998; 53: 743-53.
7. WEINRAUCH Y, FOREMAN A, SHU C et al.: Extracellular accumulation of potently microbicidal bactericidal/permeability-increasing protein and p15s in an evolving sterile rabbit peritoneal inflammatory exsudate. J Clin Invest 1995; 95: 1916-24.
8. LI R, LIU T, WONG BS et al.: Identification of an epitope in the C terminus of normal prion protein whose expression is modulated by binding events in the N terminus. J Mol Biol 2000; 301: 567-73.
9. BEAMER LJ, CARROLL SF, EISENBERG D: Crystal structure of human BPI and two bound phospholipids at 2.4 Angstrom resolution. Science 1997; 276: 1861-4.
10. AEBI C, THEILER F, AEBISCHER CC, SCHOENI MH: Autoantibodies directed against bactericidal/permeability-increasing protein in patients with cystic fibrosis: Association with microbial respiratory tract colonization. Pediatr Infect Dis J 2000; 19: 207-12.
11. STOVER CK, PHAM XQ, ERWIN AL et al.: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 2000; 406: 959-64.
12. BLANK M, KRAUSE I, FRIDKIN M et al.: Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109: 797-804.
13. CAPODICI C, CHEN S, SIDORCZYK Z, ELSBACH P, WEISS J: Effect of lipopolysaccharide (LPS) chain length on interactions of bactericidal/permeability- increasing protein and its bioactive 23-kilodalton NH2-terminal fragment with isolated LPS and intact Proteus mirabilis and Escherichia coli. Infect Immun 1994; 62: 259-65.
14. GALLIN MY, JACOBI AB, BUTTNER DW, SCHONBERGER O, MARTI T, ERTTMANN KD: Human autoantibody to defensin: Disease association with hyperreactive onchocerciasis (sowda). J Exp Med 1995; 182: 41-7.
15. CANNY G, LEVY O, FURUTA GT et al.: Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci USA 2002; 99: 3902-7.